| Literature DB >> 30551129 |
M Yé1, M Kagoné1, A Sié1, C Bagagnan1, H Sanou1, O Millogo1, V Duclos2, I Tinto1, Gilles Bibeau3.
Abstract
Background: In Burkina Faso, access to health services for women, children and people living with HIV/AIDS (PLWHAs) remains limited. Mobile telephony offers an alternative solution for reaching these individuals. The objective of the study was to improve equity of access to health care and information among women and PLWHAs by reinforcing community participation.Entities:
Mesh:
Year: 2018 PMID: 30551129 PMCID: PMC6294034 DOI: 10.1093/pubmed/fdy196
Source DB: PubMed Journal: J Public Health (Oxf) ISSN: 1741-3842 Impact factor: 2.341
Fig. 1Nouna mHealth project area within the HDSS. HDSS, Health and Demographic Surveillance System.
Fig. 2mHealth platform structure.
Evolution of indicators in intervention area between 2013 and 2016
| Indicators | 2013 (%) (A) | 2016 (%) (B) | Difference 2016–13 (C) | Progress (%) (D)** | |
|---|---|---|---|---|---|
| PNC1 | 40 (349/873) | 86.77 (931/1073) | 46.75 | 117 | <0.0001 |
| PNC4 | 52.8 (461/873) | 56.66 (608/1073) | 3.88 | 7.34 | 0.088 |
| TV2+ | 62 (543/873) | 89.00 (955/1073) | 26.95 | 43.46 | <0.0001 |
| IPT2 | 85 (743/873) | 83.69 (898/1073) | −1.26 | 0 | 0.42 |
| HRP | 56 (18/32) | 100 (61/61) | 44 | 78.57 | <0.0001 |
| PMTCT | 78.33 (684/873) | 85.27 (915/1073) | 6.93 | 8.84 | 0.0001 |
| AD | 62.5 (446/713) | 82.07 (760/926) | 19.54 | 30.77 | <0.0001 |
| PPC | 62 (429/691) | 54.99 (380/691) | 7 | 11.29 | 0.08 |
| CP | 50.8 (444/873) | 43.43 (76/175) | −6.96 | 0 | 0.07 |
| Polio birth | 100 (586/586) | 100 (716/716) | 0 | 0 | >0.05 |
| BCG | 100 (586/586) | 100 (716/716) | 0 | 0 | >0.05 |
| Combined | 68.18 | 80.18 | 0.85 |
PNC1, prenatal consultation 1; PNC4, prenatal consultation 4; TV2+, tetanus vaccine, two or more doses; IPT2, intermittent preventive treatment for malaria in pregnant women second dose; HRP, referred high-risk pregnancies; PMTCT, prevention of mother-to-child transmission of HIV; AD, assisted delivery; PPC, postpartum consultation; CP, contraceptive prevalence; BCG, Bacillus Calmette-Guerin.
**Level of progress (D) = (B−C/) A*100.
Evolution of indicators in control area between 2013 and 2016
| Indicateurs | 2013 (A) | 2016 (B) | Difference (C) | Level of progress (D)** | |
|---|---|---|---|---|---|
| PNC1 | 45.09 (410/911) | 75.93 (743/978) | 30.84 | 68.40 | <0.0001 |
| PNC4 | 54.87 (499/911) | 45.47 (445/978) | −9.4 | −17.13 | <0.0001 |
| TV2+ | 87.15 (794/911) | 72.59 (778/978) | −7.65 | −8.78 | <0.0001 |
| IPT2 | 92.9 (846/911) | 95.60 (710/978) | −20.31 | −21.86 | 0.011 |
| HRP | 68.75 (11/16) | 100 (9/9) | 31.25 | 45% | <0.0001 |
| PMTCT | 93.62 (853/911) | 83.59 (818/978) | −10.03 | −10.71 | <0.0001 |
| AD | 93.37 (710/761) | 89.97 (734/816) | −3.4 | −3.64 | 0.0086 |
| PPC | 40.23 (271/674) | 64.36 (466/723) | 24.13 | 59.98 | <0.0001 |
| CP | 74.86 (261/349) | 65.93 (246/374) | −9.09 | −12.14 | 0.008 |
| Polio birth | 85.86 (662/771) | 89.08 (737/827) | 3.22 | 3,75 | 0.051 |
| BCG | 85.86 (662/771) | 89.08 (737/827) | 3.22 | 3.75 | 0.051 |
| Combined | M1 = 77.70 | M2 = 79.24 | 0.429 |
Comparison of averages for the test and control areas at the end of December 2016
| Indicators | Test area 2016 (%) | Control area 2016 (%) | Difference (%) | |
|---|---|---|---|---|
| PNC1 | 86.77 (931/1073) | 75.93 (743/978) | 10.84 | <0.0001 |
| PNC4 | 56.66 (608/1073) | 45.47 (445/978) | 11.19 | <0.0001 |
| TV2+ | 89.00 (955/1073) | 72.59 (778/978) | 9.5 | <0.0001 |
| IPT2 | 83.69 (898/1073) | 95.60 (710/978) | 11.1 | <0.0001 |
| HRP | 100 (61/61) | 100 (9/9) | 0 | >0.05 |
| PMTCT | 85.27 (915/1073) | 83.59 (818/978) | 1.68 | 0.427 |
| AD | 82.07 (760/926) | 89.97 (734/816) | −7.9 | <0.0001 |
| PPC | 54.99 (380/691) | 64.36 (466/723) | −9.37 | 0.0003 |
| CP | 43.43 (76/175) | 65.93 (246/374) | −22.5 | <0.0001 |
| Polio birth | 100 (716/716) | 89.08 (737/827) | 10.92 | <0.0001 |
| BCG | 100 (716/716) | 89.08 (737/827) | 10.92 | <0.0001 |
| Combined mean | M1 = 80.16 | M2 = 79.22 | 0.451 ( |
PNC1, prenatal consultation 1; PNC4, prenatal consultation 4; TV2+, tetanus vaccine, two or more doses; IPT2, intermittent preventive treatment for malaria in pregnant women second dose; HRP, referred high-risk pregnancies; PMTCT, prevention of mother-to-child transmission of HIV; AD, assisted delivery; PPC, postpartum consultation; CP, contraceptive prevalence; BCG, Bacillus Calmette-Guerin.
Baseline comparison between intervention and control areas in 2013
| Indicators | Test area 2013 (%) | Control area 2013 (%) | Difference test area–control area 2013 | |
|---|---|---|---|---|
| PNC1 | 40 (349/873) | 45.09 (410/911) | −5.09 | 0.032 |
| PNC4 | 52.8 (461/873) | 54.87 (499/911) | −2.07 | 0.38 |
| TV2+ | 62 (543/873) | 87.15 (794/911) | −25.15 | <0.0001 |
| IPT2 | 85 (743/873) | 92.9 (846/911) | −7.9 | <0.0001 |
| HRP | 56 (18/32) | 68.75 (11/16) | −12.75 | 0.399 |
| PMTCT | 78.33 (684/873) | 93.62 (853/911) | −15.29 | <0.0001 |
| AD | 62.5 (446/713) | 93.37 (710/761) | −30.87 | <0.0001 |
| PPC | 62 (429/691) | 40.23 (271/674) | 21.77 | <0.0001 |
| CP | 50.8 (444/873) | 74.86 (261/349) | −24.06 | <0.0001 |
| Polio birth | 100 (586/586) | 85.86 (662/771) | 5.09 | <0.0001 |
| BCG | 100 (586/586) | 85.86 (662/771) | 5.09 | <0.0001 |
| Combined mean | M1 = 68.18 | M1 = 74.77 | 0.221 |